Skip to main content
. Author manuscript; available in PMC: 2010 Apr 19.
Published in final edited form as: Arch Gen Psychiatry. 2008 Jul;65(7):841–850. doi: 10.1001/archpsyc.65.7.841

Figure 5.

Figure 5

Cue-elicited craving and treatment outcome for the genotype × medication groups. When treated with olanzapine, there were no significant differences between individuals with the CT genotype and those with the TT genotype in mean cue-elicited craving (A). When treated with placebo, individuals with the CT genotype demonstrated significantly greater mean cue-elicited craving (B). During a 12-week trial, individuals with the CT and TT genotypes drank at similar levels when treated with olanzapine (C). In contrast, individuals with the CT genotype drank significantly more during placebo treatment (D). Error bars represent SE.